Nalaganje...
Pegvisomant in acromegaly: an update
BACKGROUND: In 2007, we published an opinion document to review the role of pegvisomant (PEG) in the treatment of acromegaly. Since then, new evidence emerged on the biochemical and clinical effects of PEG and on its long-term efficacy and safety. AIM: We here reviewed the emerging aspects of the us...
Shranjeno v:
| izdano v: | J Endocrinol Invest |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer International Publishing
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5443862/ https://ncbi.nlm.nih.gov/pubmed/28176221 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40618-017-0614-1 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|